- AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
- AlloVir Reports Full Year 2020 Financial Results
- AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
- AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
- AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses
- Company Profile for AlloVir
- Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting
- Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy
Allovir Inc (ALVR:NSQ) closed at 36.56, -25.33% below its 52-week high of 48.96, set on Dec 23, 2020.
18.15Jul 30 202048.96Dec 23 2020
Markit short selling activity
|Market cap||2.38bn USD|
|EPS (TTM)||-1.09 |
Data delayed at least 15 minutes, as of Feb 26 2021 21:00 GMT.